本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Vaxcyte, Inc.

67.88
+2.864.40%
成交量:19.75萬
成交額:1,316.97萬
市值:101.00億
市盈率:-8.87
高:67.97
開:64.78
低:64.78
收:65.02
52周最高:90.75
52周最低:39.87
股本:1.49億
流通股本:1.36億
量比:0.30
換手率:0.15%
股息:- -
股息率:- -
每股收益(TTM):-7.6496
每股收益(LYR):-5.6333
淨資產收益率:-36.51%
總資產收益率:-22.61%
市淨率:3.66
市盈率(LYR):-12.05

資料載入中...

2026/10/07

[補充]招股説明書

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026/10/05

關聯方擬減持公告

Form 144 | Vaxcyte, Inc. 高管 Cowan Elvia 擬減持19000股普通股,總市值約164.81萬美元
2026/10/05

關聯方擬減持公告

Form 144 | Vaxcyte, Inc. 高管 James Wassil 擬減持18000股普通股,合計約156.13萬美元
2026/10/05

重要事件披露

Form 8-K - Current report
2026/10/01

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/09/09

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/09/04

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/09/03

重要事件披露

Form 8-K - Current report
2026/09/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/08/11

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/07

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/06

超過5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/08/05

重要事件披露

Form 8-K - Current report
2026/08/04

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/08/04

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/07/28

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/07/15

重要事件披露

Form 8-K - Current report
2026/07/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities